Recombinant full-length parathyroid hormone (1-84)

Drugs

Volumn 66, Issue 18, 2006, Pages 2371-2381

  Moen, Marit D ^a   Scott, Lesley J ^b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; PREOTACT; RALOXIFENE; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; UNCLASSIFIED DRUG; VITAMIN D;

AREA UNDER THE CURVE; BONE DENSITY; BONE REMODELING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MONOTHERAPY; NAUSEA; NONHUMAN; OPTIMAL DRUG DOSE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SINGLE DRUG DOSE; VERTEBRA FRACTURE; VOMITING;

EID: 33846107351     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666180-00008     Document Type: Review

References (34)

1. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005 Dec; 115 (12): 3318-25
2. Delmas PD, Rizzoli R, Cooper C, et al. Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation. Osteoporos Int 2005 Jan; 16 (1): 1-5
3. McClung M. Parathyroid hormone for the treatment of osteoporosis. Obstet Gynecol Surv 2004; 59 (12): 826-32
4. Murray TM, Rao LG, Divieti P, et al. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl-terminal ligands. Endocr Rev 2005 Feb; 26 (1): 78-113
5. Potts JT. Parathyroid hormone: past and present. J Endocrinol 2005 Dec; 187 (3): 311-25
6. Carter PH, Schipani E. The roles of parathyroid hormone and calcitonin in bone remodeling: prospects for novel therapeutics. Endocr Metab Immune Disord Drug Targets 2006 Mar; 6 (1): 59-76
7. Whitfield JF, Morley P, Willick GE. Parathyroid hormone, its fragments and their analogs for the treatment of osteoporosis. Treat Endocrinol 2002; 1 (3): 175-90
8. Nycomed. Preotact (full-length parathyroid hormone): product information (EU) [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/ preotact/preotactM.htm [Accessed 2006 May 31]
9. Schwietert HR, Groen EWJ, Sollie FAE, et al. Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers. Clin Pharmacol Ther 1997 Mar; 61: 360-76
10. Groen EWJ, Schwietert HR, Van Marle SP, et al. Multiple dose administration of recombinant human parathyroid hormone (rhPTH (1-84)) in healthy postmenopausal volunteers [abstract no. 525]. Therapie 1995; 50 Suppl.
11. Hodsman AB, Hanley DA, Ettinger MP, et al. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003 Nov; 88 (11): 5212-20
12. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003 Sep 25; 349 (13): 1207-15
13. Moreau IA, Smith SY, Guldberg RE, et al. Treatment of osteopenic rhesus monkeys with parathyroid hormone 1-84 for 16 months improves vertebral trabecular bone quantity and quality [abstract no. M415]. J Bone Miner Res 2005 Sep; 20 Suppl. 1: S412
14. Kimmel DB, Bozzato RP, Kronis KA, et al. The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 1993 Apr; 132 (4): 1577-84
15. 2 to stimulate femoral trabecular bone growth in ovariectomized rats. Calcif Tissue Int 1997 Jan; 60 (1): 26-9
16. Ejersted C, Andreassen TT, Oxlund H, et al. Human parathyroid hormone (1-34) and (1-84) increase the mechanical strength and thickness of cortical bone in rats. J Bone Miner Res 1993 Sep; 8 (9): 1097-101
17. Samnegard E, Iwaniec UT, Cullen DM, et al. Maintenance of cortical bone in human parathyroid hormone(1-84)-treated ovariectomized rats. Bone 2001 Mar; 28 (3): 251-60
18. NPS Pharmaceuticals. NPS reports positive PREOS study results [online]. Available from URL: http://www.npsp.com [Accessed 2006 Jun 14]
19. Fox J, Smith S, Jolette J, et al. A no observable carcinogenic effect dose level identified in Fischer 344 rats following daily treatment with PTH(1-84) for 2 years: role of the c-terminal PTH receptor? 33rd European Symposium on Calcified Tissues; 2006 May 10-14; Prague
20. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002 May-Jun; 30 (3): 312-21
21. Eli Lilly and Company. Forteo teriparatide (rDNA origin) injection: prescribing information (US) [online]. Available from URL: http://www.fda.gov [Accessed 2006 Jun 14]
22. Greenspan SL, Bone HG, Marriott TB, et al. Preventing the first vertebral fracture in postmenopausal women with low bone mass using PTH(1-84): results from the TOP study [abstract no. 1222]. J Bone Miner Res 2005 Sep; 20 Suppl. 1: S56
23. Miller PD. PTH(1-84) prevents vertebral fractures in post menopausal women with higher fracture risk: results from the TOP study [abstract no. P425]. 33rd European Symposium on Calcified Tissues; 2006 May 10-14; Prague
24. Bogado CE, Zanchetta JR, Mango A, et al. Effects of parathyroid hormone 1-84 on cortical and trabecular bone at the hip as assessed by QCT: results at 18 months from the TOP Study [abstract no. 1083]. J Bone Miner Res 2005 Sep; 20 Suppl. 1: S22
25. Bogado CE, Zanchetta JR, Gordon CL, et al. Treatment of postmenopausal osteoporotic women with parathyroid hormone (1-84) for 18 months decreases BMD but does not affect indices of bone strength at the distal radius [abstract no. F383]. J Bone Miner Res 2006; 21 Suppl. 1
26. Ettinger MP, Marriott TB. Recombinant human parathyroid hormone 1-84 (PTH) reduces the incidence of multiple new vertebral fractures and new fracture severity in postmenopausal osteoporotic women [abstract no. P321MO]. Osteoporos Int 2006; 17 Suppl. 2: S90
27. Greenspan SL, Marriott TB, Hanley DA, et al. Full-length PTH prevents first vertebral fracture in postmenopausal women with osteoporosis: results from the TOP study [abstract]. 5th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis; 2005 Mar 16-19; Rome
28. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005 Aug 11; 353 (6): 555-65
29. Fogelman I, Christiansen C, Spector T, et al. Safety and efficacy of PTH(1-84) at 18 and 24 months in women with postmenopausal osteoporosis receiving hormone therapy: results from the POWER study [abstract no. 1080]. J Bone Miner Res 2005 Sep; 20 Suppl. 1: S21-2
30. European Medicines Agency. Scientific discussion (Preotact) [online]. Available from URL: http://www.emea.eu.int/humandocs/PDFs/EPAR/preotact/ PreotactEparScientificDen.pdf [Accessed 2006 May 31]
31. Greenspan SL, Hanley DA, Morris S, et al. Bone turnover markers and BMD remain elevated in postmenopausal osteoporotic women through a full 24 months of treatment with human parathyroid hormone 1-84 (PTH) [abstract no. F389]. 28th Annual Meeting of the American Society for Bone and Mineral Research; 2006 Sep 15-19; Philadelphia (PA)
32. Data on file. Nycomed, 2006
33. Compston J, Silverman S, Mathisen A, et al. Parathyroid hormone (1-84) is effective in patients with a wide range of clinical risk factors [abstract no. OP0126]. 2006 Annual European Congress of Rheumatology; 2006 Jun 21-24; Amsterdam
34. Fox J, Miller MA, Recker RR, et al. Treatment of postmenopausal osteoporotic women with parathyroid hormone 1-84 for 18 months increases cancellous bone formation and improves cancellous architecture: A study of iliac crest biopsies using histomorphometry and micro computed tomography. J Musculoskelet Neuronal Interact 2005 Dec; 5 (4): 356-7